drugset / Trial / NCT06174935
Low Dose Atropine for Symptomatic Vitreous Floaters
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2024-06-01
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atropine | Other / unclassified | 0.01 % | Other |